F-18 FDG Positron Emission Tomography and Benign Fractures

Purpose F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) has been used extensively in the imaging of cancer, including metastatic skeletal disease. Although uptake into benign osseous disease has been reported, there is very limited information regarding uptake into benign fractures. This report provides additional information regarding the appearance of benign fractures on FDG-PET images. Materials and Methods Four case reports of FDG-PET scanning are presented in patients with proved benign fractures. Results In three of these cases, FDG uptake was noted in fractures when images were obtained 17 days to 8 weeks after injury, with the most avid uptake observed when FDG-PET imaging was performed 17 days after fracture. In the patient in whom imaging was performed 8 weeks after fracture, no uptake of FDG was seen in a benign fracture. Conclusions Fractures may accumulate FDG to varying degrees, and false-positive findings may occur when FDG-PET imaging is performed to assess for metastases, although the different pattern of uptake and clinical correlation usually allows accurate differentiation of fracture from skeletal metastases.

[1]  I. Fogelman,et al.  The role of positron emission tomography in the management of bone metastases , 2000, Cancer.

[2]  G. V. von Schulthess,et al.  Chronic osteomyelitis of the femur: value of PET imaging , 2000, European Radiology.

[3]  S. Reske,et al.  FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Rigo,et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer , 1998, European Journal of Nuclear Medicine.

[6]  I. Fogelman,et al.  Fluorine-18-FDG PET in Paget's disease of bone. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  K. Hubner,et al.  Increased F-18 FDG Accumulation in an Acute Fracture , 1994, Clinical nuclear medicine.

[9]  T. Ekfors,et al.  F-18 Fluorodeoxyglucose: Its Potential in Differentiating Between Stress Fracture and Neoplasia , 1989, Clinical nuclear medicine.